Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR technologies for the treatment of Duchenne muscular dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy - 3 Nov 2021

Choi Eunyoung, Koo Taeyoung

Abstract excerpt

The emerging clustered regularly interspaced short palindromic repeats (CRISPR)-mediated genome editing technologies have progressed remarkably in recent years, opening up the potential of precise genome editing as a therapeutic approach to treat various diseases. The CRISPR-CRISPR-associated (Cas) system is an attractive platform for the treatment of Duchenne muscular dystrophy (DMD), which is a neuromuscular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Management
Share to CRISPR-Cas Systems
Share to Dystrophin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Editing

Share to Genetic Therapy

Share to Muscular Dystrophy, Duchenne

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 33823301
DOI: 10.1016/j.ymthe.2021.04.002
PMCID: PMC8571109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR technologies for the treatment of Duchenne muscular dystrophy.PMID 33823301Read ↗

CRISPR Therapeutics for Duchenne Muscular DystrophySemantic proximity Read ↗

Methods of CRISPR/Cas9 Exon Skipping for Duchenne Muscular DystrophySemantic proximity Read ↗

Role of CRISPR/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies.Semantic proximity Read ↗

Correction of muscular dystrophies by CRISPR gene editing.Semantic proximity Read ↗

Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging TherapiesSemantic proximity Read ↗

Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Duchenne muscular dystrophy: an updated review of common available therapiesSemantic proximity Read ↗

CRISPR-Generated Animal Models of Duchenne Muscular DystrophySemantic proximity Read ↗

CRISPR/Cas correction of muscular dystrophies.Semantic proximity Read ↗

Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.Semantic proximity Read ↗

Neuromuscular disease: CRISPR/Cas9 gene-editing platform corrects mutations associated with Duchenne muscular dystrophy.Semantic proximity Read ↗

Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.